FocusOn Healthcare
  • Women's Health
  • Bone Health
  • Urology
  • Cardiology
  • Gastroenterology
  • Neurology
  • Oncology
  • Resource Centers:
  • Women's Health
  • Bone Health
  • Urology
  • Cardiology
  • Gastroenterology
  • Neurology
  • Oncology

Expression of HER2 in urothelial carcinoma and its significance

  • Current Urology
  • May 2025
Urothelial Cancer Awareness Month Peer Reviewed Articles

Read Full Article

Abstract

Objectives 

We explored the expression levels and clinical significance of human epidermal growth factor receptor 2 (HER2) in urothelial carcinoma (UC) tissues.

Materials and methods 

Patient data were reviewed, and 111 paraffin specimens of UC obtained from the Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, from 2020 to 2021 were collected. Immunohistochemistry was used to detect HER2 protein expression in all UC tumor tissues. The χ2 and Fisher exact tests were used to analyze the relationship between HER2 protein expression and clinicopathological data (sex, age, histopathological diagnosis, invasiveness, histopathological grade, maximum tumor diameter, muscle invasion, regional lymph node metastasis, and clinical stage).

Results 

In this study, 92 cases (82.88%) showed HER2 protein expression, and there was a statistically significant difference in the distribution of HER2 positivity (immunohistochemistry 2+ and 3+) according to the pathological grades of UC (p = 0.021). Human epidermal growth factor receptor 2 positivity was not associated with sex, age, histopathological diagnosis, invasiveness, maximum tumor diameter, muscle invasion, regional lymph node metastasis, or clinical stage (all p < 0.05).

Conclusions 

Human epidermal growth factor receptor 2 protein is highly expressed in UC, and its expression may be closely related to the high pathological grade of UC.

You might also like:

Emerging strategies: conservative management of upper tract urothelial carcinoma

Novel Computational Pipeline Enables Reliable Diagnosis of Inverted Urothelial Papilloma and Distinguishes It From Urothelial Carcinoma

Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.

Germline genetic variants in cancers of the bladder, renal pelvis, ureter, or urethra.

Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants.

Share

Modal body text goes here.

FocusOn logo
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2025 Wolters Kluwer. All right reserved.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|
|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.

Read More